Summary
Abbott Laboratories reported increased net sales for the second quarter and first six months of 2024, driven primarily by growth in its Medical Devices, Nutritional Products, and Established Pharmaceutical Products segments. This growth was achieved despite a significant decline in COVID-19 testing sales and unfavorable foreign exchange impacts due to a stronger U.S. dollar. Despite revenue growth, net earnings decreased year-over-year for both the quarter and the first six months, impacted by higher operating costs and expenses, including a loss on the sale of a non-core business and increased selling, general, and administrative expenses. However, operational cash flow remained strong, indicating continued business health. Investors should monitor the ongoing legal proceedings related to infant formula and the company's significant tax exposure with the IRS, which could materially impact future results.
Financial Highlights
51 data points| Revenue | $10.38B |
| Cost of Revenue | $4.60B |
| Gross Profit | $5.77B |
| R&D Expenses | $698.00M |
| SG&A Expenses | $2.94B |
| Operating Expenses | $8.71B |
| Operating Income | $1.67B |
| Net Income | $1.30B |
| EPS (Basic) | $0.74 |
| EPS (Diluted) | $0.74 |
| Shares Outstanding (Basic) | 1.74B |
| Shares Outstanding (Diluted) | 1.75B |
Key Highlights
- 1Total net sales increased by 4.0% (7.5% excluding foreign exchange) in Q2 2024 and 3.1% (6.3% excluding foreign exchange) for the first six months of 2024, demonstrating underlying business growth.
- 2Medical Devices segment continues to be a strong performer, with a 10.2% (12.4% excluding foreign exchange) increase in Q2 2024 sales, driven by double-digit growth in Diabetes Care, Electrophysiology, and Structural Heart.
- 3COVID-19 testing-related sales significantly declined, contributing to a 5.3% decrease in the Diagnostics segment sales in Q2 2024, a trend that is expected to continue.
- 4Net earnings for Q2 2024 decreased to $1.302 billion from $1.375 billion in Q2 2023, and for the first six months decreased to $2.527 billion from $2.693 billion, impacted by increased operating costs and a loss on the sale of a non-core business.
- 5The company is facing significant tax disputes with the IRS, with potential liabilities for 2017-2020 tax years amounting to over $1 billion.
- 6A jury awarded $495 million in a lawsuit alleging Abbott's infant formula products caused necrotizing enterocolitis (NEC); Abbott plans to appeal this verdict.
- 7Gross profit margin improved to 51.1% in Q2 2024 from 50.1% in Q2 2023, indicating effective cost management and pricing strategies.